Item 1.01. Entry into a Material Definitive Agreement.
Effective February 6, 2020, Innovate Biopharmaceuticals, Inc. (the "Company")
and the holders of the Company's outstanding short-term common stock purchase
warrants (each a "Warrant" and collectively the "Warrants"), originally issued
March 18, 2019, amended the Warrants to extend the exercise period of each
Warrant by six months. The Warrants, as amended, are exercisable for up to an
aggregate of 4,181,068 shares of the Company's common stock, par value $0.0001
per share, until September 18, 2020. Except as specifically amended, all terms
and conditions of each Warrant shall remain in full force and effect and shall
not be affected by this amendment.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. Description
Form of Amendment to Short-term Common Stock Purchase
Exhibit 4.1 Warrant, dated February 6, 2020
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses